



MicroPhage MRSA Screening Test*

The Practical Answer

The MicroPhage MRSA screening test identifies methicillin-resistant *S. aureus* (MRSA) when you need rapid results in a simple-to-use, cost sensible format.

The Centers for Disease Control and Prevention (CDC) estimate that over 22,000 Americans died in 2004 – up from 13,300 in 1992 – due to antibiotic resistant pathogens, chiefly MRSA.¹ And resistance to methicillin among *S. aureus* isolates is also a growing problem: now more than 60-percent of all *S. aureus* infections have been found to be MRSA in many United States hospitals.

Active surveillance of colonization can help significantly reduce MRSA infections.

The MicroPhage MRSA screening test will enable hospitals and other institutions to quickly and affordably screen newly admitted patients to help reduce subsequent infection and transmission.

MicroPhage's bacteriophage amplification technology will provide the performance of molecular results at a price that is more in line with chromagenic culture media. The easy-to-use platform allows for simple, unbatched test starts and rapid batched or unbatched results, perfect for an early morning delivery of hospital-wide results when Infection Control can best use them. The MicroPhage MRSA screening test is ideal for institutions concerned with screening for MRSA in their patients that may not have the capacity for molecular or traditional microbiology.



Powerful Diagnostics in the Palm of your Hand

MicroPhage delivers a high-value diagnostic in an easy-to-use platform:

- Simple to perform:
3 minutes hands-on time; visual interpretation; unbatched
- Rapid time to results:
10 hours; stable results in up to 24 hours, start-to-finish*
- High specificity:
High 90s*
- High sensitivity:
Mid 90s*

* This test is not cleared by the FDA and not yet available for sale in the U.S. market.

¹ Farr and Jarvis. Infect. Control Hosp. Epidemiol. (23): 65-68.